Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.
about
Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM)A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infectionPapillomaviruses: Viral evolution, cancer and evolutionary medicineNaturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study.Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis.National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United StatesReadability and Coherence of Department/Ministry of Health HPV Information.Prophylactic HPV vaccination: past, present, and future.Antibody responses following incident anal and penile infection with human papillomavirus in teenage men who have sex with men.HPV SEROSTATUS PRE- AND POST-VACCINATION IN A RANDOMIZED PHASE II PREPAREDNESS TRIAL AMONG YOUNG WESTERN CAPE, SOUTH AFRICAN WOMEN: THE EVRI TRIAL.Association of Streptococcus gallolyticus subspecies gallolyticus with colorectal cancer: Serological evidence.Why Human Papillomavirus Acute Infections Matter.Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact
P2860
Q33916553-E3770436-A54B-4AD6-B84C-DE8A6DE2874EQ34970731-85537F66-C97E-47BD-8749-C9CB48BFBC5AQ35166924-40557DC9-028B-41E3-AA8B-7CEFF08096B9Q35861286-E2E0557B-AFA9-4397-BA5B-2554E1BE2015Q35886910-32EE4405-B04B-48C8-8100-02C52E49922CQ36675963-3533F36C-70BE-4293-BDA7-0F09A89486B5Q36745242-F897A04F-39E6-4391-9F72-C10F3BFCFE24Q37173134-1A9ABC4A-2F2D-4EE0-A0BA-93625FDF256CQ38389748-CDE7660E-5F2C-44B9-B116-2377BF5D836EQ38597567-04C7EDF2-3E13-4496-B7F0-8E19CC42C7E4Q39908571-D8DA1F67-F43E-44A8-BA93-3A856CA97C9EQ40211544-DED9F243-CD36-4995-A499-BBD10E456BFBQ40355199-2EEFCC0F-75BA-4360-9D0D-3CC44BB7A092Q41921051-B69F7C4C-FF4E-4C59-A8F9-23154971C6ADQ47549756-9CCCE622-EFDE-422B-98EC-E31FD2759E54Q58799763-CA169191-64E4-4351-BA86-8A1FF21E4E46
P2860
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Risk of newly detected infecti ...... f the control arm of PATRICIA.
@ast
Risk of newly detected infecti ...... f the control arm of PATRICIA.
@en
type
label
Risk of newly detected infecti ...... f the control arm of PATRICIA.
@ast
Risk of newly detected infecti ...... f the control arm of PATRICIA.
@en
prefLabel
Risk of newly detected infecti ...... f the control arm of PATRICIA.
@ast
Risk of newly detected infecti ...... f the control arm of PATRICIA.
@en
P2093
P2860
P50
P356
P1476
Risk of newly detected infecti ...... f the control arm of PATRICIA.
@en
P2093
Alice Raillard
Barbara Romanowski
Dominique Descamps
Dominique Rosillon
F Xavier Bosch
Fred Y Aoki
Gary Dubin
Genara Limson
Henry Kitchener
Julio C Teixeira
P2860
P304
P356
10.1093/INFDIS/JIU139
P407
P50
P577
2014-03-08T00:00:00Z